SEC Form 4 · accession 0001209191-17-064704
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lewis Clayton Cantley Jr.
Director
Period of report
Dec 6, 2017
Accepted (ET)
Dec 8, 2017 · 4:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Dec 6, 2017 | S | 543 | $57.90 | D | 80,851 | D | |
| Common stockF2,F3 | Dec 6, 2017 | S | 542 | $57.90 | D | 80,892 | I | See footnote |
| Common stockF4 | Dec 6, 2017 | S | 253 | $58.95 | D | 80,598 | D | |
| Common stockF4,F3 | Dec 6, 2017 | S | 254 | $58.95 | D | 80,638 | I | See footnote |
| Common stockF5 | Dec 6, 2017 | S | 204 | $60.01 | D | 80,394 | D | |
| Common stockF5,F3 | Dec 6, 2017 | S | 204 | $60.01 | D | 80,434 | I | See footnote |
| Common stockF6 | Dec 7, 2017 | S | 288 | $59.68 | D | 80,106 | D | |
| Common stockF6,F3 | Dec 7, 2017 | S | 288 | $59.68 | D | 80,146 | I | See footnote |
| Common stockF7 | Dec 7, 2017 | S | 631 | $60.45 | D | 79,475 | D | |
| Common stockF7,F3 | Dec 7, 2017 | S | 631 | $60.45 | D | 79,515 | I | See footnote |
| Common stockF8 | holding | — | — | — | 20,803 | I | See footnote | |
| Common stockF9 | holding | — | — | — | 20,803 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $57.48 to $58.30. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Shares held by Vicki Lee Sato, who is the reporting person's spouse.
- F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $58.58 to $59.21. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $59.62 to $60.55. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F6The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $58.99 to $59.95. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F7The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.79. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F8Shares held by grantor retained annuity trusts for the benefit of the reporting person and his two children, of which the reporting person is trustee and sole annuitant.
- F9Shares held by grantor retained annuity trusts for the benefit of the reporting person's spouse and their two children, of which the reporting person's spouse is trustee and sole annuitant.